Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xininurad
- Development stage
- Phase 1
- Lead developer
- Evopoint Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xininurad (XNW3009) is an orally administered small molecule drug that acts as a selective inhibitor of the human urate transporter 1 (URAT1, also known as SLC22A12 protein). By inhibiting URAT1 in the kidneys, xininurad increases renal excretion of uric acid and lowers serum uric acid levels. It is being developed primarily for the treatment of hyperuricaemia and gout. The drug was originally developed by Sinovent and is currently being advanced by Evopoint Biosciences. Clinical trials have reached Phase II for gout and Phase III for hyperuricaemia.
02
Targets
URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on xininurad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xininurad.